Bausch + Lomb Announces Appointment of Karen L. Ling to Board of Directors
28 Février 2024 - 2:00PM
Business Wire
Richard De Schutter to Retire from Board
Following 2024 Annual Meeting
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye
health company dedicated to helping people see better to live
better, today announced that Karen L. Ling has been appointed to
its Board of Directors (the “Board”), effective immediately.
Current director Richard De Schutter will retire from the Board
effective as of the company’s 2024 Annual Meeting of Shareholders
(the “Annual Meeting”). With Ms. Ling’s appointment, the Board has
been temporarily expanded to 11 members and is expected to revert
to 10 directors following the Annual Meeting.
“Since my return to the company, Richard has been a trusted
advisor,” said Brent Saunders, chairman and CEO, Bausch + Lomb. “I
join the rest of the Board in thanking him for his service, and
wishing him well as he pursues his many other interests.”
Mr. Saunders continued, “With her extensive industry leadership
experience and time as a public company director, Karen brings
significant human capital management, corporate governance and
shareholder engagement expertise to the organization. We’re
confident her perspectives will be highly additive in the boardroom
as Bausch + Lomb continues its evolution.”
Ms. Ling stated, “I have long admired Bausch + Lomb’s reputation
in eye health, and am excited to join such a dynamic and innovative
organization as it executes an ambitious global growth strategy. I
look forward to helping the company deliver value for all
stakeholders in 2024 and beyond.”
About Karen L. Ling
Ms. Ling is the former Executive Vice President and Chief Human
Resources Officer at American International Group, Inc. and, prior
to that, at Allergan. She previously held senior human resources
roles at Merck and Wyeth. Ms. Ling is currently a director – and
chair of the Compensation and Human Capital Management Committee –
of iRythym Technologies and has served on the Boards of
Mallinckrodt Plc and TherapeuticsMD Inc. She also serves as a
member of the Advisory Committee of Galderma. Additionally, Ms.
Ling is a member of the board of two nonprofits: ExpandEd Schools
and the JED Foundation. She holds a B.A. in Economics from Yale
University and a J.D. from the Boston University School of Law.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift
of sight for millions of people around the world – from birth
through every phase of life. Its comprehensive portfolio of
approximately 400 products includes contact lenses, lens care
products, eye care products, ophthalmic pharmaceuticals,
over-the-counter products and ophthalmic surgical devices and
instruments. Founded in 1853, Bausch + Lomb has a significant
global research and development, manufacturing and commercial
footprint with approximately 13,000 employees and a presence in
nearly 100 countries. Bausch + Lomb is headquartered in Vaughan,
Ontario with corporate offices in Bridgewater, New Jersey. For more
information, visit www.bausch.com and connect with us on X,
LinkedIn, Facebook and Instagram.
Forward-looking Statements
This news release may contain forward-looking statements, which
may generally be identified by the use of the words “anticipates,”
“hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,”
“may,” “believes,” “estimates,” “potential,” “target,” or
“continue” and variations or similar expressions. These statements
are based upon the current expectations and beliefs of management
and are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include,
but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb’s filings with the U.S. Securities and Exchange
Commission and the Canadian Securities Administrators, which
factors are incorporated herein by reference. Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch + Lomb undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
© 2024 Bausch + Lomb.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240228431306/en/
Media: T.J. Crawford tj.crawford@bausch.com (908)
705-2851 Investor: George Gadkowski
george.gadkowski@bausch.com (877) 354-3705 (toll free) (908) 927-0735
Bausch plus Lomb (NYSE:BLCO)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Bausch plus Lomb (NYSE:BLCO)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024